Last reviewed · How we verify
Plasma-derived AT-III concentrate
At a glance
| Generic name | Plasma-derived AT-III concentrate |
|---|---|
| Sponsor | Grifols Biologicals, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass (PHASE3)
- Safety, Pharmacokinetics and Efficacy of an ATIII Concentrate (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Plasma-derived AT-III concentrate CI brief — competitive landscape report
- Plasma-derived AT-III concentrate updates RSS · CI watch RSS
- Grifols Biologicals, LLC portfolio CI